0000275053 false 2020 Q2--12-31 1 1.25 0000275053 2020-01-01 2020-06-30 xbrli:shares 0000275053 2020-07-24 iso4217:USD 0000275053 2020-06-30 0000275053 2019-12-31 0000275053 2020-04-01 2020-06-30 0000275053 2019-04-01 2019-06-30 iso4217:USD xbrli:shares 0000275053 2019-01-01 2019-06-30 0000275053 us-gaap:CommonStockMember 2019-12-31 0000275053 us-gaap:RetainedEarningsMember 2019-12-31 0000275053 us-gaap:NoncontrollingInterestMember 2019-12-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000275053 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000275053 2020-01-01 2020-03-31 0000275053 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000275053 us-gaap:CommonStockMember 2020-03-31 0000275053 us-gaap:RetainedEarningsMember 2020-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2020-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000275053 2020-03-31 0000275053 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000275053 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000275053 us-gaap:CommonStockMember 2020-06-30 0000275053 us-gaap:RetainedEarningsMember 2020-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2020-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000275053 us-gaap:CommonStockMember 2018-12-31 0000275053 us-gaap:RetainedEarningsMember 2018-12-31 0000275053 us-gaap:NoncontrollingInterestMember 2018-12-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000275053 2018-12-31 0000275053 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000275053 2019-01-01 2019-03-31 0000275053 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000275053 us-gaap:CommonStockMember 2019-03-31 0000275053 us-gaap:RetainedEarningsMember 2019-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2019-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000275053 2019-03-31 0000275053 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000275053 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000275053 us-gaap:CommonStockMember 2019-06-30 0000275053 us-gaap:RetainedEarningsMember 2019-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2019-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000275053 2019-06-30 0000275053 natr:AccruedSeveranceandRentCostsMember 2020-06-30 0000275053 natr:AccruedSeveranceandRentCostsMember 2019-12-31 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2017-07-11 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2020-06-11 natr:numberOfBorrowingsIncreases xbrli:pure 0000275053 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2017-07-11 2017-07-11 0000275053 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2019-12-31 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2017-07-11 2017-07-11 0000275053 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember srt:MinimumMember 2020-06-11 2020-06-11 0000275053 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2020-06-11 2020-06-11 0000275053 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2020-06-30 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2020-06-11 2020-06-11 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2020-06-30 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-04-21 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-04-21 2020-04-21 0000275053 natr:IndicativeIndexMember us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-04-21 2020-04-21 0000275053 natr:IndicativeIndexMember us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-06-30 natr:numberOfPayments 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-06-30 0000275053 natr:PaycheckProtectionProgramMember us-gaap:NotesPayableToBanksMember 2020-04-14 0000275053 natr:PaycheckProtectionProgramMember us-gaap:NotesPayableToBanksMember 2020-06-30 0000275053 natr:A2012IncentivePlanMember 2012-12-31 0000275053 natr:A2012IncentivePlanMember 2015-01-01 2015-12-31 0000275053 srt:MaximumMember natr:IncentivePlan2009Member 2020-06-30 0000275053 srt:MaximumMember natr:TimeBasedStockOptionsMember 2020-01-01 2020-06-30 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2020-01-01 2020-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2019-12-31 0000275053 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2020-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2020-06-30 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2019-12-31 0000275053 natr:A2012IncentivePlanMember srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000275053 srt:MaximumMember natr:A2012IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000275053 srt:DirectorMember natr:A2012IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000275053 srt:DirectorMember natr:A2012IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000275053 srt:DirectorMember natr:A2012IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000275053 natr:A2012IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000275053 natr:A2012IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000275053 natr:A2012IncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000275053 natr:TimeBasedRestrictedStockUnitsRSUsMember natr:A2012IncentivePlanMember 2020-01-01 2020-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember natr:A2012IncentivePlanMember 2020-01-01 2020-06-30 0000275053 natr:NetSalesandOperatingIncomeTargetsMember natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember natr:A2012IncentivePlanMember 2020-01-01 2020-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000275053 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000275053 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember 2020-04-01 2020-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember 2019-04-01 2019-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember 2020-01-01 2020-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember 2019-01-01 2019-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember srt:MaximumMember 2020-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember 2020-06-30 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember srt:MinimumMember 2020-01-01 2020-06-30 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember srt:MaximumMember 2020-01-01 2020-06-30 natr:segment 0000275053 natr:NSPAmericasNSPRussiaCentralandEasternEuropeandNSPChinaMember 2019-10-01 2019-12-31 0000275053 natr:SynergyWorldWideMember 2019-10-01 2019-12-31 0000275053 natr:AsiaSegmentMember 2020-04-01 2020-06-30 0000275053 natr:AsiaSegmentMember 2019-04-01 2019-06-30 0000275053 natr:AsiaSegmentMember 2020-01-01 2020-06-30 0000275053 natr:AsiaSegmentMember 2019-01-01 2019-06-30 0000275053 natr:EuropeSegmentMember 2020-04-01 2020-06-30 0000275053 natr:EuropeSegmentMember 2019-04-01 2019-06-30 0000275053 natr:EuropeSegmentMember 2020-01-01 2020-06-30 0000275053 natr:EuropeSegmentMember 2019-01-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember 2020-04-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember 2019-04-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember 2020-01-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember 2019-01-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2020-04-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2019-04-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2020-01-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2019-01-01 2019-06-30 0000275053 country:CN 2020-04-01 2020-06-30 0000275053 country:CN 2020-01-01 2020-06-30 0000275053 country:CN 2019-04-01 2019-06-30 0000275053 country:CN 2019-01-01 2019-06-30 0000275053 country:US 2020-04-01 2020-06-30 0000275053 country:US 2019-04-01 2019-06-30 0000275053 country:US 2020-01-01 2020-06-30 0000275053 country:US 2019-01-01 2019-06-30 0000275053 country:KR 2020-04-01 2020-06-30 0000275053 country:KR 2019-04-01 2019-06-30 0000275053 country:KR 2020-01-01 2020-06-30 0000275053 country:KR 2019-01-01 2019-06-30 0000275053 natr:OtherCountriesMember 2020-04-01 2020-06-30 0000275053 natr:OtherCountriesMember 2019-04-01 2019-06-30 0000275053 natr:OtherCountriesMember 2020-01-01 2020-06-30 0000275053 natr:OtherCountriesMember 2019-01-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:GeneralHealthProductsMember 2020-04-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:GeneralHealthProductsMember 2019-04-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:GeneralHealthProductsMember 2020-01-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:GeneralHealthProductsMember 2019-01-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:ImmunityProductsMember 2020-04-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:ImmunityProductsMember 2019-04-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:ImmunityProductsMember 2020-01-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:ImmunityProductsMember 2019-01-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:CardiovascularProductsMember 2020-04-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:CardiovascularProductsMember 2019-04-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:CardiovascularProductsMember 2020-01-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:CardiovascularProductsMember 2019-01-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:DigestiveProductsMember 2020-04-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:DigestiveProductsMember 2019-04-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:DigestiveProductsMember 2020-01-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:DigestiveProductsMember 2019-01-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:PersonalCareProductsMember 2020-04-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:PersonalCareProductsMember 2019-04-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:PersonalCareProductsMember 2020-01-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:PersonalCareProductsMember 2019-01-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:WeightManagementProductsMember 2020-04-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:WeightManagementProductsMember 2019-04-01 2019-06-30 0000275053 natr:AsiaSegmentMember natr:WeightManagementProductsMember 2020-01-01 2020-06-30 0000275053 natr:AsiaSegmentMember natr:WeightManagementProductsMember 2019-01-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:GeneralHealthProductsMember 2020-04-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:GeneralHealthProductsMember 2019-04-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:GeneralHealthProductsMember 2020-01-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:GeneralHealthProductsMember 2019-01-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:ImmunityProductsMember 2020-04-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:ImmunityProductsMember 2019-04-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:ImmunityProductsMember 2020-01-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:ImmunityProductsMember 2019-01-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:CardiovascularProductsMember 2020-04-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:CardiovascularProductsMember 2019-04-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:CardiovascularProductsMember 2020-01-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:CardiovascularProductsMember 2019-01-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:DigestiveProductsMember 2020-04-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:DigestiveProductsMember 2019-04-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:DigestiveProductsMember 2020-01-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:DigestiveProductsMember 2019-01-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:PersonalCareProductsMember 2020-04-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:PersonalCareProductsMember 2019-04-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:PersonalCareProductsMember 2020-01-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:PersonalCareProductsMember 2019-01-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:WeightManagementProductsMember 2020-04-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:WeightManagementProductsMember 2019-04-01 2019-06-30 0000275053 natr:EuropeSegmentMember natr:WeightManagementProductsMember 2020-01-01 2020-06-30 0000275053 natr:EuropeSegmentMember natr:WeightManagementProductsMember 2019-01-01 2019-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2020-04-01 2020-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2019-04-01 2019-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2020-01-01 2020-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2019-01-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:ImmunityProductsMember 2020-04-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:ImmunityProductsMember 2019-04-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:ImmunityProductsMember 2020-01-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:ImmunityProductsMember 2019-01-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:CardiovascularProductsMember 2020-04-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:CardiovascularProductsMember 2019-04-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:CardiovascularProductsMember 2020-01-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:CardiovascularProductsMember 2019-01-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:DigestiveProductsMember 2020-04-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:DigestiveProductsMember 2019-04-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:DigestiveProductsMember 2020-01-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:DigestiveProductsMember 2019-01-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:PersonalCareProductsMember 2020-04-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:PersonalCareProductsMember 2019-04-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:PersonalCareProductsMember 2020-01-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:PersonalCareProductsMember 2019-01-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:WeightManagementProductsMember 2020-04-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:WeightManagementProductsMember 2019-04-01 2019-06-30 0000275053 natr:NorthAmericaSegmentMember natr:WeightManagementProductsMember 2020-01-01 2020-06-30 0000275053 natr:NorthAmericaSegmentMember natr:WeightManagementProductsMember 2019-01-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:GeneralHealthProductsMember 2020-04-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:GeneralHealthProductsMember 2019-04-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:GeneralHealthProductsMember 2020-01-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:GeneralHealthProductsMember 2019-01-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:ImmunityProductsMember 2020-04-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:ImmunityProductsMember 2019-04-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:ImmunityProductsMember 2020-01-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:ImmunityProductsMember 2019-01-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:CardiovascularProductsMember 2020-04-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:CardiovascularProductsMember 2019-04-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:CardiovascularProductsMember 2020-01-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:CardiovascularProductsMember 2019-01-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:DigestiveProductsMember 2020-04-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:DigestiveProductsMember 2019-04-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:DigestiveProductsMember 2020-01-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:DigestiveProductsMember 2019-01-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:PersonalCareProductsMember 2020-04-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:PersonalCareProductsMember 2019-04-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:PersonalCareProductsMember 2020-01-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:PersonalCareProductsMember 2019-01-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:WeightManagementProductsMember 2020-04-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:WeightManagementProductsMember 2019-04-01 2019-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:WeightManagementProductsMember 2020-01-01 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember natr:WeightManagementProductsMember 2019-01-01 2019-06-30 0000275053 country:US 2020-06-30 0000275053 country:US 2019-12-31 0000275053 us-gaap:NonUsMember 2020-06-30 0000275053 us-gaap:NonUsMember 2019-12-31 0000275053 natr:AsiaSegmentMember 2020-06-30 0000275053 natr:AsiaSegmentMember 2019-12-31 0000275053 natr:EuropeSegmentMember 2020-06-30 0000275053 natr:EuropeSegmentMember 2019-12-31 0000275053 natr:NorthAmericaSegmentMember 2020-06-30 0000275053 natr:NorthAmericaSegmentMember 2019-12-31 0000275053 natr:LatinAmericaAndOtherSegmentMember 2020-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2019-12-31 natr:claim 0000275053 natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember 2020-06-30 0000275053 natr:NonIncomeTaxMember 2020-06-30 0000275053 natr:NonIncomeTaxMember 2019-12-31 0000275053 srt:MinimumMember natr:NonIncomeTaxMember 2020-06-30 0000275053 srt:MaximumMember natr:NonIncomeTaxMember 2020-06-30 0000275053 us-gaap:PendingLitigationMember 2020-06-30 0000275053 us-gaap:PendingLitigationMember 2019-12-31 0000275053 natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember 2020-01-01 2020-06-30 0000275053 natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember srt:MinimumMember 2020-06-30 0000275053 natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember srt:MaximumMember 2020-06-30 0000275053 srt:SubsidiariesMember us-gaap:NotesReceivableMember natr:NaturesSunshineProductsChinaMember 2020-04-01 2020-06-30 0000275053 srt:SubsidiariesMember us-gaap:NotesReceivableMember natr:NaturesSunshineProductsChinaMember natr:CompanysJointVenturePartnerMember 2019-01-01 2019-06-30 0000275053 srt:SubsidiariesMember us-gaap:NotesReceivableMember natr:NaturesSunshineProductsChinaMember 2020-01-01 2020-06-30 0000275053 srt:SubsidiariesMember us-gaap:NotesReceivableMember natr:NaturesSunshineProductsChinaMember natr:CompanysJointVenturePartnerMember 2019-04-01 2019-06-30 0000275053 srt:SubsidiariesMember natr:NaturesSunshineProductsChinaMember 2020-06-30 0000275053 srt:SubsidiariesMember natr:NaturesSunshineProductsChinaMember 2019-12-31 0000275053 srt:SubsidiariesMember natr:NaturesSunshineProductsChinaMember natr:CompanysJointVenturePartnerMember 2020-06-30 0000275053 srt:SubsidiariesMember natr:NaturesSunshineProductsChinaMember natr:CompanysJointVenturePartnerMember 2019-12-31 0000275053 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0000275053 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000275053 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000275053 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000275053 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000275053 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000275053 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000275053 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 natr:product_category 0000275053 srt:MaximumMember 2020-01-01 2020-06-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________________
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission File Number: 001-34483
NATURE’S SUNSHINE PRODUCTS, INC.
(Exact name of Registrant as specified in its charter)

Utah |  | 87-0327982
(State or other jurisdiction of |  | (IRS Employer
incorporation or organization) |  | Identification No.)

2901 Bluegrass Boulevard, Suite 100
Lehi, Utah 84043
(Address of principal executive offices and zip code)
(801) 341-7900
(Registrant’s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, no par value | NATR | Nasdaq Capital Market

Indicate by check mark whether the registrant; (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o |  | Accelerated filer x
Non-accelerated filer o |  | Smaller reporting company ☒
|  | Emerging growth company ☐

Table of Contents
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ý.
The number of shares of Common Stock, no par value, outstanding on July 24, 2020, was 19,510,764 shares.

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC.
FORM 10-Q
For the Quarter Ended June 30, 2020
Table of Contents

Part I. Financial Information |  |  | 4
| Item 1. | Financial Statements (Unaudited) | 4
|  | Condensed Consolidated Balance Sheets | 4
|  | Condensed Consolidated Statements of Income | 5
|  | Condensed Consolidated Statements of Comprehensive Income | 7
|  | Condensed Consolidated Statements of Changes in Shareholders’ Equity | 7
|  | Condensed Consolidated Statements of Cash Flows | 9
|  | Notes to Condensed Consolidated Financial Statements | 10
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 33
| Item 4. | Controls and Procedures | 33
Part II. Other Information |  |  | 34
| Item 1. | Legal Proceedings | 34
| Item 1A. | Risk Factors | 34
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 36
| Item 3. | Defaults Upon Senior Securities | 36
| Item 4. | Mine Safety Disclosures | 36
| Item 5. | Other Information | 36
| Item 6. | Exhibits | 37

2

Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information included or incorporated herein by reference in this report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. For example, information appearing under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” includes forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are more fully described in this report, including the risks set forth under “Risk Factors” in Item 1A, and in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, but include the following:
•adverse impacts of the global COVID-19 pandemic;
•laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
•extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
•legal challenges to the Company's direct selling program or to the classification of its independent distributors;
•impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
•the Company’s ability to attract and retain independent distributors;
•the loss of one or more key independent distributors who have a significant sales network;
•the Company’s joint venture for operations in China with Fosun Industrial Co., Ltd.;
•registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
•cybersecurity threats and exposure to data loss;
•the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
•reliance on information technology infrastructure;
•the effect of fluctuating foreign exchange rates;
•liabilities and obligations arising from improper activity by the Company’s independent distributors;
•failure of the Company’s independent distributors to comply with advertising laws;
•changes to the Company’s independent distributor compensation plans;
•geopolitical issues and conflicts;
•negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s customers to purchase products;
•risks associated with the manufacturing of the Company's products;
•uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
•changes in tax laws, treaties or regulations, or their interpretation;
•actions on trade relations by the U.S. and foreign governments;
•product liability claims;
•the sufficiency of trademarks and other intellectual property rights; and
•our cannabidiol (CBD) product line is subject to varying, rapidly changing laws, regulations, and rules.
All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report. Throughout this report, we refer to Nature’s Sunshine Products, Inc., together with our subsidiaries, as "we," "us," "our," "our Company" or “the Company.”
3

Table of Contents
PART I FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)

| June 30, 2020 |  | December 31, 2019
Assets |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 70,255 |  |  | $ | 53,629 |
Accounts receivable, net of allowance for doubtful accounts of $423 and $407, respectively | 7,075 |  |  | 7,319 |
Inventories | 50,166 |  |  | 46,666 |
Prepaid expenses and other | 6,577 |  |  | 5,091 |
Total current assets | 134,073 |  |  | 112,705 |
Property, plant and equipment, net | 56,687 |  |  | 59,512 |
Operating lease right-of-use assets | 20,572 |  |  | 23,951 |
Investment securities - trading | 1,035 |  |  | 1,150 |
Intangible assets, net | 511 |  |  | 567 |
Deferred income tax assets | 3,977 |  |  | 4,899 |
Other assets | 10,074 |  |  | 10,284 |
Total assets | $ | 226,929 |  |  | $ | 213,068 |
Liabilities and Shareholders’ Equity |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 4,100 |  |  | $ | 4,406 |
Accrued volume incentives and service fees | 20,172 |  |  | 18,893 |
Accrued liabilities | 25,424 |  |  | 25,531 |
Deferred revenue | 1,845 |  |  | 1,266 |
Related party notes payable | 1,537 |  |  | 1,518 |
Income taxes payable | 2,038 |  |  | 1,392 |
Current portion of operating lease liabilities | 4,416 |  |  | 4,941 |
Current portion of note payable | 2,407 |  |  | — |
Total current liabilities | 61,939 |  |  | 57,947 |
Liability related to unrecognized tax benefits | 1,364 |  |  | 1,499 |
Long-term portion of operating lease liabilities | 17,530 |  |  | 20,213 |
Long-term note payable | 2,967 |  |  | — |
Deferred compensation payable | 1,035 |  |  | 1,150 |
Deferred income tax liabilities | 1,645 |  |  | 1,655 |
Other liabilities | 1,214 |  |  | 1,168 |
Total liabilities | 87,694 |  |  | 83,632 |
Shareholders’ equity: |  |  |
Common stock, no par value, 50,000 shares authorized, 19,510 and 19,410 shares issued and outstanding, respectively | 136,661 |  |  | 135,741 |
Retained earnings | 13,409 |  |  | 4,693 |
Noncontrolling interest | 650 |  |  | 227 |
Accumulated other comprehensive loss | (11,485) |  |  | (11,225) |
Total shareholders’ equity | 139,235 |  |  | 129,436 |
Total liabilities and shareholders’ equity | $ | 226,929 |  |  | $ | 213,068 |

See accompanying notes to condensed consolidated financial statements.
4

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited)

| Three Months Ended June 30, |  |
| 2020 |  | 2019
Net sales | $ | 87,286 |  |  | $ | 90,724 |
Cost of sales | 23,017 |  |  | 23,865 |
Gross profit | 64,269 |  |  | 66,859 |
Operating expenses: |  |  |
Volume incentives | 29,165 |  |  | 31,302 |
Selling, general and administrative | 28,504 |  |  | 31,019 |
Operating income | 6,600 |  |  | 4,538 |
Other income, net | 1,509 |  |  | 306 |
Income before provision for income taxes | 8,109 |  |  | 4,844 |
Provision for income taxes | 1,976 |  |  | 2,215 |
Net income | 6,133 |  |  | 2,629 |
Net income (loss) attributable to noncontrolling interests | 379 |  |  | (60) |
Net income attributable to common shareholders | $ | 5,754 |  |  | $ | 2,689 |
Basic and diluted net income per common share: |  |  |
Basic earnings per share attributable to common shareholders | $ | 0.30 |  |  | $ | 0.14 |
Diluted earnings per share attributable to common shareholders | $ | 0.29 |  |  | $ | 0.14 |
Weighted average basic common shares outstanding | 19,491 |  |  | 19,291 |
Weighted average diluted common shares outstanding | 19,783 |  |  | 19,602 |

See accompanying notes to condensed consolidated financial statements.
5

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited)

| Six Months Ended June 30, |  |
| 2020 |  | 2019
Net sales | $ | 183,212 |  |  | $ | 181,996 |
Cost of sales | 47,698 |  |  | 47,294 |
Gross profit | 135,514 |  |  | 134,702 |
Operating expenses: |  |  |
Volume incentives | 62,183 |  |  | 62,315 |
Selling, general and administrative | 59,569 |  |  | 64,871 |
Operating income | 13,762 |  |  | 7,516 |
Other income (loss), net | (901) |  |  | 258 |
Income before provision for income taxes | 12,861 |  |  | 7,774 |
Provision for income taxes | 3,722 |  |  | 3,416 |
Net income | 9,139 |  |  | 4,358 |
Net income (loss) attributable to noncontrolling interests | 423 |  |  | (88) |
Net income attributable to common shareholders | $ | 8,716 |  |  | $ | 4,446 |
Basic and diluted net income per common share: |  |  |
Basic earnings per share attributable to common shareholders | $ | 0.45 |  |  | $ | 0.23 |
Diluted earnings per share attributable to common shareholders | $ | 0.44 |  |  | $ | 0.23 |
Weighted average basic common shares outstanding | 19,472 |  |  | 19,280 |
Weighted average diluted common shares outstanding | 19,725 |  |  | 19,596 |

See accompanying notes to condensed consolidated financial statements.
6

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Amounts in thousands)
(Unaudited)

| Three Months Ended June 30, |  |
| 2020 |  | 2019
Net income | $ | 6,133 |  |  | $ | 2,629 |
Foreign currency translation loss (net of tax) | (151) |  |  | (530) |
Total comprehensive income | $ | 5,982 |  |  | $ | 2,099 |

| Six Months Ended June 30, |  |
| 2020 |  | 2019
Net income | $ | 9,139 |  |  | $ | 4,358 |
Foreign currency translation loss (net of tax) | (260) |  |  | (846) |
Total comprehensive income | $ | 8,879 |  |  | $ | 3,512 |

See accompanying notes to condensed consolidated financial statements.
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(Amounts in thousands)
(Unaudited)

| Common Stock |  |  |  | Retained Earnings (Accumulated Deficit) |  | Noncontrolling Interest |  | Accumulated Other Comprehensive Loss |  | Total
| Shares |  | Amount |  |  |  |  |  |  |  |
Balance at December 31, 2019 | 19,410 |  |  | $ | 135,741 |  |  | $ | 4,693 |  |  | $ | 227 |  |  | $ | (11,225) |  |  | $ | 129,436 |
Share-based compensation expense | — |  |  | 394 |  |  | — |  |  | — |  |  | — |  |  | 394 |
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax | 60 |  |  | (159) |  |  | — |  |  | — |  |  | — |  |  | (159) |
Net income | — |  |  | — |  |  | 2,962 |  |  | 44 |  |  | — |  |  | 3,006 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (109) |  |  | (109) |
Balance at March 31, 2020 | 19,470 |  |  | $ | 135,976 |  |  | $ | 7,655 |  |  | $ | 271 |  |  | $ | (11,334) |  |  | $ | 132,568 |
Share-based compensation expense | — |  |  | 736 |  |  | — |  |  | — |  |  | — |  |  | 736 |
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax | 40 |  |  | (51) |  |  | — |  |  | — |  |  | — |  |  | (51) |
Net income | — |  |  | — |  |  | 5,754 |  |  | 379 |  |  | — |  |  | 6,133 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (151) |  |  | (151) |
Balance at June 30, 2020 | 19,510 |  |  | $ | 136,661 |  |  | $ | 13,409 |  |  | $ | 650 |  |  | $ | (11,485) |  |  | $ | 139,235 |

7

Table of Contents

| Common Stock |  |  |  | Retained Earnings (Accumulated Deficit) |  | Noncontrolling Interest |  | Accumulated Other Comprehensive Loss |  | Total
| Shares |  | Amount |  |  |  |  |  |  |  |
Balance at December 31, 2018 | 19,204 |  |  | $ | 133,684 |  |  | $ | (2,072) |  |  | $ | 63 |  |  | $ | (11,107) |  |  | $ | 120,568 |
Share-based compensation expense | — |  |  | 230 |  |  | — |  |  | — |  |  | — |  |  | 230 |
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax | 69 |  |  | (189) |  |  | — |  |  | — |  |  | — |  |  | (189) |
Net income (loss) | — |  |  | — |  |  | 1,757 |  |  | (28) |  |  | — |  |  | 1,729 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (316) |  |  | (316) |
Balance at March 31, 2019 | 19,273 |  |  | $ | 133,725 |  |  | $ | (315) |  |  | $ | 35 |  |  | $ | (11,423) |  |  | $ | 122,022 |
Share-based compensation expense | — |  |  | 621 |  |  | — |  |  | — |  |  | — |  |  | 621 |
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax | 29 |  |  | (4) |  |  | — |  |  | — |  |  | — |  |  | (4) |
Net income (loss) | — |  |  | — |  |  | 2,689 |  |  | (60) |  |  | — |  |  | 2,629 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (530) |  |  | (530) |
Balance at June 30, 2019 | 19,302 |  |  | $ | 134,342 |  |  | $ | 2,374 |  |  | $ | (25) |  |  | $ | (11,953) |  |  | $ | 124,738 |

See accompanying notes to condensed consolidated financial statements.
8

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)

| Six Months Ended June 30, |  |
| 2020 |  | 2019
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
Net income | $ | 9,139 |  |  | $ | 4,358 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |
Provision for doubtful accounts | 17 |  |  | 30 |
Depreciation and amortization | 5,070 |  |  | 4,987 |
Non-cash lease expense | 2,257 |  |  | 2,792 |
Share-based compensation expense | 1,130 |  |  | 851 |
Loss on sale of property, plant and equipment | 6 |  |  | 3 |
Deferred income taxes | 912 |  |  | 365 |
Purchase of trading investment securities | (35) |  |  | (57) |
Proceeds from sale of trading investment securities | 146 |  |  | 105 |
Realized and unrealized losses (gains) on investments | 4 |  |  | (173) |
Foreign exchange losses (gains) | 996 |  |  | (205) |
Changes in assets and liabilities: |  |  |
Accounts receivable | 173 |  |  | (1,035) |
Inventories | (4,114) |  |  | (2,052) |
Prepaid expenses and other current assets | (1,523) |  |  | (259) |
Other assets | (69) |  |  | (767) |
Accounts payable | (138) |  |  | (1,226) |
Accrued volume incentives and service fees | 1,523 |  |  | (235) |
Accrued liabilities | 59 |  |  | (6,203) |
Deferred revenue | 582 |  |  | 1,039 |
Lease liabilities | (2,072) |  |  | (2,340) |
Income taxes payable | 607 |  |  | (1,207) |
Liability related to unrecognized tax benefits | (135) |  |  | (40) |
Deferred compensation payable | (115) |  |  | 125 |
Net cash provided by (used in) operating activities | 14,420 |  |  | (1,144) |
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
Purchases of property, plant and equipment | (2,210) |  |  | (2,774) |
Net cash used in investing activities | (2,210) |  |  | (2,774) |
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
Principal payments of revolving credit facility | — |  |  | (547) |
Proceeds from revolving credit facility | — |  |  | 547 |
Proceeds from note payable | 5,374 |  |  | — |
Tax benefit from stock awards | (210) |  |  | (193) |
Net cash provided by (used in) financing activities | 5,164 |  |  | (193) |
Effect of exchange rates on cash and cash equivalents | (748) |  |  | (186) |
Net increase (decrease) in cash and cash equivalents | 16,626 |  |  | (4,297) |
Cash and cash equivalents at the beginning of the period | 53,629 |  |  | 50,638 |
Cash and cash equivalents at the end of the period | $ | 70,255 |  |  | $ | 46,341 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |  |  |
Cash paid for income taxes, net of refunds | $ | 2,143 |  |  | $ | 3,895 |
Cash paid for interest | 3 |  |  | 63 |

See accompanying notes to condensed consolidated financial statements.
9

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) Basis of Presentation
We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent distributors who uses the products themselves or resells them to consumers.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2020, and for the three and six-month periods ended June 30, 2020 and 2019. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2020.
It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.
Use of Estimates
The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors and those differences could have a material effect on our financial position and results of operations.
The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to Manager and Distributor incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions.
Noncontrolling Interests
Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.4 million and $0.4 million for the three and six months ended June 30, 2020, respectively. Net losses attributable to the noncontrolling interests were $0.1 million and $0.1 million for the three and six months ended June 30, 2019, respectively. As of June 30, 2020 and December 31, 2019, noncontrolling interests were $0.7 million and $0.2 million, respectively.
Restructuring Related Accruals and Expenses
We recorded $0 and $0.1 million of restructuring related expenses during the three and six months ended June 30, 2020, respectively. We recorded $0.4 million and $0.2 million restructuring related expenses during the three and six months ended June 30, 2019. Accrued severance and restructuring related costs were $10,000 and $0.4 million as of June 30, 2020 and December 31, 2019, respectively.
10

Table of Contents
Recent Accounting Pronouncements
In August 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820 based on the consideration of costs and benefits to promote the appropriate exercise and discretion by entities when considering fair value measurement disclosures and to clarify that materiality is an appropriate consideration of entities and their auditors when evaluating disclosure requirements. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. The adoption of this ASU did not have a significant impact on our Consolidated Financial Statements.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the quarters and the recognition of deferred tax liabilities for outside basis differences. The amendments in this update are effective for reporting periods beginning after December 15, 2020, with early adoption permitted. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.
(2) Inventories
The composition of inventories is as follows (dollar amounts in thousands):

| June 30, 2020 |  | December 31, 2019
Raw materials | $ | 14,697 |  |  | $ | 13,329 |
Work in progress | 1,288 |  |  | 1,426 |
Finished goods | 34,181 |  |  | 31,911 |
Total inventories | $ | 50,166 |  |  | $ | 46,666 |

(3) Investment Securities - Trading
Our trading securities portfolio totaled $1.0 million at June 30, 2020, and $1.2 million at December 31, 2019, and generated gains of $93,000 and $40,000 for the three months ended June 30, 2020 and 2019, respectively, and losses of $4,000 and gains of $173,000 for the six months ended June 30, 2020 and 2019, respectively.
(4) Revolving Credit Facility and Other Obligations
On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 11, 2020 the credit agreement was amended to extend the term to mature on July 1, 2023. The amendment also allows for additional borrowings of $15.0 million or up to three separate increases of no less than $5.0 million each. We pay interest on any borrowings under the Credit Agreement, which through June 10, 2020, was at LIBOR plus 1.25 percent (3.05 percent as of December 31, 2019), and an annual commitment fee of 0.2 percent on the unused portion of the commitment. Interest under the amended Credit Agreement is at LIBOR, or the Index floor of 0.75 percent, plus 2.25 percent (3.00 percent as of June 30, 2020), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. We are required to settle our net borrowings under the Credit Agreement only upon maturity, and as a result, have classified prior outstanding borrowings as non-current on our condensed consolidated balance sheet. At June 30, 2020, there was no outstanding balance under the Credit Agreement.
The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable balance, inventory balance and other assets. As of June 30, 2020, we were in compliance with the debt covenants set forth in the Credit Agreement.
On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million, that matures sixty months from the Base Date, which must not be later than April 30, 2021 (the "Capital Credit Agreement"). We pay interest on any borrowings under the Capital Credit Agreement at the Indicative Index
11

Table of Contents
plus 2.75 percent (3.50 percent as of June 30, 2020). We are required to settle our borrowings under the Capital Credit Agreement in sixty monthly payments, each equal to 1.82 percent of the loan amount. The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. As of June 30, 2020, there was no outstanding balance under the Capital Credit Agreement.
On April 14, 2020, we obtained a loan (the “Loan”) from Bank of America, B.A. in the amount of $5.4 million under the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The PPP is a loan designed to provide an incentive for qualifying businesses to maintain their employees on the payroll despite significant economic uncertainty. We applied to receive the Loan based on the significant economic uncertainty facing the Company in the U.S. and globally.
The Loan matures on April 14, 2022 and bears interest at a rate of 1.00 percent per annum, payable monthly commencing on November 15, 2020. We may prepay the Loan at any time prior to maturity with no prepayment penalties. The principal amount of the Loan and accrued interest are eligible for forgiveness after either eight weeks or 26 weeks if we use the Loan proceeds for qualifying expenses, including payroll, rent, and utilities during the eight week period commencing on the date the Loan has been advanced. The amount of the Loan eligible for forgiveness will be reduced to the extent that we have (i) terminated full-time employees during the period commencing February 15, 2020 and ending April 26, 2020 and (ii) reduced salaries (beyond a statutorily prescribed threshold) during the eight week period commencing on the date the Loan has been advanced. We will be obligated to repay any portion of the principal amount of the Note that is not forgiven, together with accrued interest thereon at the rate set forth above until such unforgiven portion is paid in full. As of June 30, 2020, there was $5.4 million outstanding under the PPP, $2.4 million of which was classified as current.
.(5) Net Income Per Share
Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.
Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2020 and 2019 (dollar and share amounts in thousands, except for per share information):

| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Net income attributable to common shareholders | $ | 5,754 |  |  | $ | 2,689 |  |  | $ | 8,716 |  |  | $ | 4,446 |
Basic weighted average shares outstanding | 19,491 |  |  | 19,291 |  |  | 19,472 |  |  | 19,280 |
Basic earnings per share attributable to common shareholders | $ | 0.30 |  |  | $ | 0.14 |  |  | $ | 0.45 |  |  | $ | 0.23 |
Diluted shares outstanding: |  |  |  |  |  |  |
Basic weighted-average shares outstanding | 19,491 |  |  | 19,291 |  |  | 19,472 |  |  | 19,280 |
Stock-based awards | 292 |  |  | 311 |  |  | 253 |  |  | 316 |
Diluted weighted-average shares outstanding | 19,783 |  |  | 19,602 |  |  | 19,725 |  |  | 19,596 |
Diluted earnings per share attributable to common shareholders | $ | 0.29 |  |  | $ | 0.14 |  |  | $ | 0.44 |  |  | $ | 0.23 |
Dilutive shares excluded from diluted-per-share amounts: |  |  |  |  |  |  |
Stock options | 844 |  |  | 445 |  |  | 844 |  |  | 445 |
Anti-dilutive shares excluded from diluted-per-share amounts: |  |  |  |  |  |  |
Stock options | 264 |  |  | 838 |  |  | 239 |  |  | 862 |

12

Table of Contents
Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.
(6) Capital Transactions
Share-Based Compensation
During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events.
We also maintain a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares.
Stock Options
Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options.
Stock option activity for the six-month period ended June 30, 2020, is as follows (amounts in thousands, except per share information):

| Number of Shares |  | Weighted Average Exercise Price Per Share
Options outstanding at December 31, 2019 | 290 |  |  | $ | 11.49 |
Granted | — |  |  | — |
Forfeited or canceled | — |  |  | — |
Exercised | (25) |  |  | 5.79 |
Options outstanding at June 30, 2020 | 265 |  |  | 12.03 |

There was no share-based compensation expense for the three- and six-month periods ended June 30, 2020 and 2019 for stock options. As of June 30, 2020 and December 31, 2019, there was no unrecognized share-based compensation expense related to the grants described above.
At June 30, 2020, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 265,000 shares of common stock was $11,000. At December 31, 2019, the aggregate intrinsic value of outstanding and exercisable options to purchase 290,000 shares of common stock was $0.1 million.
For the six-month periods ended June 30, 2020 and 2019, we issued 25,000 and 1,000 shares of common stock upon the exercise of stock options at an average exercise price of $5.79 and $2.35 per share, respectively. The aggregate intrinsic value of options exercised during the six-month periods ended June 30, 2020 and 2019, was $0.1 million and $10,000, respectively.
13

Table of Contents
For the six-month periods ended June 30, 2020 and 2019, the Company recognized $48,000 and $3,000 of tax benefits from the exercise of stock options, respectively.
As of June 30, 2020 and December 31, 2019, we did not have any unvested performance-based stock options outstanding.
Restricted Stock Units
Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to revenue and earnings growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At June 30, 2020 and December 31, 2019, there were 100,000 and 95,000 vested RSUs, respectively, granted to the Board of Directors with a restriction period.
Restricted stock unit activity for the six-month period ended June 30, 2020, is as follows (amounts in thousands, except per share information):

| Number of Shares |  | Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding at December 31, 2019 | 821 |  |  | $ | 7.43 |
Granted | 686 |  |  | 5.77 |
Forfeited | (2) |  |  | 8.68 |
Issued | (114) |  |  | 9.74 |
Restricted Stock Units outstanding at June 30, 2020 | 1,391 |  |  | 6.42 |

During the six-month period ended June 30, 2020, we granted 686,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $7.67 per share and vest in annual installments over a three-year period from the grant date or according to the restrictions for the Board of Directors noted above. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $4.51 per share and vest upon achieving share-priced targets over a three-year period from the grant date.
Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 12.7 percent for a common share.
Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of 50 percent, and a range of risk-free rates between 2.1 percent and 2.9 percent.
Share-based compensation expense for RSUs for the three-month periods ended June 30, 2020 and 2019, was approximately $0.5 million and $0.5 million, respectively. Share-based compensation expense from RSUs for the six-month periods ended June 30, 2020 and 2019, was approximately $0.8 million and $0.6 million, respectively. As of June 30, 2020 and December 31, 2019, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.4 million and $1.1 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.9 years.
Share-based compensation expense related to performance-based RSUs for the three-month periods ended June 30, 2020 and 2019, was $0.2 million and $0.1 million, respectively. Share-based compensation expense related to performance-based RSUs for the six-month periods ended June 30, 2020 and 2019, was $0.3 million and $0.2 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would recognize up to $3.5 million of potential share-
14

Table of Contents
based compensation expense. We currently expect to recognize an additional $1.3 million of that potential share-based compensation expense.
The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 24,000 and 23,000 shares for the six-month periods ended June 30, 2020 and 2019, respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.
(7) Segment Information
We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market.
Historically, our operating segments were based on brand, customer base, geographical operations with three operating business segments under the Nature’s Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China), and one operating business segment under the Synergy® WorldWide brand.
During the second quarter of 2019, we realigned into geographic focused operating business segments across brands to further align regional strategies and drive synergies in product, organizational and go-to-market strategies in local markets. Our internal reporting structure was reorganized to support the new reporting segments and the chief operating decision maker now reviews the operating results of the four segments utilizing a geographic focused format. The presentation of the comparative information has been recast to conform to the 2019 realignment.
Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses.
15

Table of Contents
Reportable business segment information is as follows (dollar amounts in thousands):

| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Net sales: |  |  |  |  |  |  |
Asia | $ | 32,757 |  |  | $ | 35,162 |  |  | $ | 63,715 |  |  | $ | 68,758 |
Europe | 15,465 |  |  | 15,075 |  |  | 36,092 |  |  | 30,672 |
North America | 34,471 |  |  | 34,620 |  |  | 73,228 |  |  | 71,143 |
Latin America and Other | 4,593 |  |  | 5,867 |  |  | 10,177 |  |  | 11,423 |
Total net sales | 87,286 |  |  | 90,724 |  |  | 183,212 |  |  | 181,996 |
Contribution margin (1): |  |  |  |  |  |  |
Asia | 16,052 |  |  | 16,677 |  |  | 30,579 |  |  | 32,402 |
Europe | 5,202 |  |  | 4,886 |  |  | 12,033 |  |  | 9,827 |
North America | 11,904 |  |  | 11,625 |  |  | 26,323 |  |  | 25,418 |
Latin America and Other | 1,946 |  |  | 2,369 |  |  | 4,396 |  |  | 4,740 |
Total contribution margin | 35,104 |  |  | 35,557 |  |  | 73,331 |  |  | 72,387 |
Selling, general and administrative expenses (2) | 28,504 |  |  | 31,019 |  |  | 59,569 |  |  | 64,871 |
Operating income | 6,600 |  |  | 4,538 |  |  | 13,762 |  |  | 7,516 |
Other income (loss), net | 1,509 |  |  | 306 |  |  | (901) |  |  | 258 |
Income before provision for income taxes | $ | 8,109 |  |  | $ | 4,844 |  |  | $ | 12,861 |  |  | $ | 7,774 |

_________________________________________
(1) Contribution margin consists of net sales less cost of sales and volume incentives expense.
(2) Service fees in China totaled $2.9 million and $4.8 million for the three and six-month periods ended June 30, 2020, respectively, compared to $2.3 million and $4.5 million for the three and six-month periods ended June 30, 2019. These service fees are included in selling, general and administrative expenses.
From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2020 and 2019, as follows (dollar amounts in thousands):

| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Net sales: |  |  |  |  |  |  |
United States | $ | 32,147 |  |  | $ | 32,194 |  |  | $ | 67,986 |  |  | $ | 66,155 |
South Korea | 14,466 |  |  | 18,923 |  |  | 30,855 |  |  | 37,451 |
Other | 40,673 |  |  | 39,607 |  |  | 84,371 |  |  | 78,390 |
| $ | 87,286 |  |  | $ | 90,724 |  |  | $ | 183,212 |  |  | $ | 181,996 |

16

Table of Contents
Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):

| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Asia |  |  |  |  |  |  |
General health | $ | 8,263 |  |  | $ | 10,752 |  |  | $ | 17,309 |  |  | $ | 18,836 |
Immune | 179 |  |  | 199 |  |  | 380 |  |  | 357 |
Cardiovascular | 9,323 |  |  | 11,561 |  |  | 18,662 |  |  | 23,394 |
Digestive | 8,391 |  |  | 7,333 |  |  | 14,547 |  |  | 12,108 |
Personal care | 1,877 |  |  | 1,820 |  |  | 4,882 |  |  | 6,087 |
Weight management | 4,724 |  |  | 3,497 |  |  | 7,935 |  |  | 7,976 |
| 32,757 |  |  | 35,162 |  |  | 63,715 |  |  | 68,758 |
Europe |  |  |  |  |  |  |
General health | $ | 6,816 |  |  | $ | 5,372 |  |  | $ | 14,776 |  |  | $ | 11,120 |
Immune | 1,370 |  |  | 1,090 |  |  | 3,814 |  |  | 2,363 |
Cardiovascular | 2,215 |  |  | 2,766 |  |  | 5,112 |  |  | 5,617 |
Digestive | 3,781 |  |  | 3,550 |  |  | 8,713 |  |  | 7,181 |
Personal care | 718 |  |  | 1,661 |  |  | 2,469 |  |  | 3,160 |
Weight management | 565 |  |  | 636 |  |  | 1,208 |  |  | 1,231 |
| 15,465 |  |  | 15,075 |  |  | 36,092 |  |  | 30,672 |
North America |  |  |  |  |  |  |
General health | $ | 14,887 |  |  | $ | 14,934 |  |  | $ | 30,351 |  |  | $ | 30,682 |
Immune | 5,049 |  |  | 3,340 |  |  | 12,847 |  |  | 7,558 |
Cardiovascular | 3,679 |  |  | 4,935 |  |  | 7,846 |  |  | 10,011 |
Digestive | 7,858 |  |  | 8,523 |  |  | 16,099 |  |  | 17,244 |
Personal care | 1,975 |  |  | 1,598 |  |  | 3,904 |  |  | 2,946 |
Weight management | 1,023 |  |  | 1,290 |  |  | 2,181 |  |  | 2,702 |
| 34,471 |  |  | 34,620 |  |  | 73,228 |  |  | 71,143 |
Latin America and Other |  |  |  |  |  |  |
General health | $ | 1,350 |  |  | $ | 1,783 |  |  | $ | 2,964 |  |  | $ | 3,395 |
Immune | 380 |  |  | 602 |  |  | 1,489 |  |  | 1,210 |
Cardiovascular | 263 |  |  | 361 |  |  | 641 |  |  | 700 |
Digestive | 2,264 |  |  | 2,645 |  |  | 4,326 |  |  | 5,181 |
Personal care | 212 |  |  | 260 |  |  | 464 |  |  | 517 |
Weight management | 124 |  |  | 216 |  |  | 293 |  |  | 420 |
| 4,593 |  |  | 5,867 |  |  | 10,177 |  |  | 11,423 |
| $ | 87,286 |  |  | $ | 90,724 |  |  | $ | 183,212 |  |  | $ | 181,996 |

From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):

| June 30, 2020 |  | December 31, 2019
Property, plant and equipment: |  |  |
United States | $ | 52,467 |  |  | $ | 54,470 |
Other | 4,220 |  |  | 5,042 |
Total property, plant and equipment, net | $ | 56,687 |  |  | $ | 59,512 |

17

Table of Contents
Total assets per segment is set forth below (dollar amounts in thousands):

| June 30, 2020 |  | December 31, 2019
Assets: |  |  |
Asia | $ | 72,608 |  |  | $ | 65,959 |
Europe | 17,952 |  |  | 15,187 |
North America | 128,358 |  |  | 124,337 |
Latin America and Other | 8,011 |  |  | 7,585 |
Total assets | $ | 226,929 |  |  | $ | 213,068 |

(8) Income Taxes
For the three months ended June 30, 2020 and 2019, our provision for income taxes, as a percentage of income before income taxes was 24.4 percent and 45.7 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2020 and 2019, our provision for income taxes, as a percentage of income before income taxes was 28.9 percent and 43.9 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent.
The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2020, was primarily attributed to transfer pricing adjustments and current year foreign losses that presently do not provide future tax benefit, as well as net unfavorable foreign tax related items.
The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2019, was primarily attributed to foreign losses during those periods that were not expected to provide future tax benefit as well as net unfavorable foreign tax related items.
The difference between the effective tax rate for the three and six months ended June 30, 2020 compared to June 30, 2019 is primarily caused by the increase in income. This increase to income causes items such as foreign losses and unfavorable tax adjustments to have a lesser impact on the effective tax rate.
As the U.S. Department of the Treasury is working on finalizing Treasury Regulations with respect to the Tax Cuts and Jobs Act (Tax Reform Act), future changes could likewise affect recorded deferred tax assets and liabilities in later periods. Management is not aware of any such additional changes that would have a material effect on our results of operations, cash flows or financial position.
Our U.S. federal income tax returns for 2016 through 2018 are open to examination for federal tax purposes. We have several foreign tax jurisdictions that have open tax years from 2014 through 2019.
As of June 30, 2020 and December 31, 2019, we had accrued $1.4 million and $1.5 million, respectively, related to unrecognized tax positions.
Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.
(9) Commitments and Contingencies
Legal Proceedings
We are party to various legal proceedings. Management cannot predict the ultimate outcome of these proceedings, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, no assurances can be given that such insurance will continue to be
18

Table of Contents
available at an acceptable cost to us, that such coverage will be sufficient to cover one or more large claims, or that the insurers will not successfully disclaim coverage as to a pending or future claim.
Non-Income Tax Contingencies
We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of June 30, 2020 and December 31, 2019, accrued liabilities were $0.3 million and $0.4 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $2.5 million.
Other Litigation
We are a party to various other legal proceedings in the United States and several foreign jurisdictions related to value-added tax assessments and other civil litigation. As of June 30, 2020 and December 31, 2019, accrued liabilities were $0.4 million and $0.4 million, respectively, related to the estimated outcome of these proceedings. In addition, we are a party to other litigation where there is a reasonable possibility that a loss may be incurred, either the losses are not considered to be probable or we cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. We believe future payments related to these matters could range from $0 to approximately $0.3 million.
(10) Related Party Transactions
During the three and six months ended June 30, 2020 and 2019, NSP China did not borrow any amounts from the Company or our joint venture partner. As of June 30, 2020 and December 31, 2019 outstanding borrowings by NSP China from the Company were $6.2 million and $6.1 million, respectively. As of June 30, 2020 and December 31, 2019 outstanding borrowings by NSP China from our joint venture partner were $1.5 million and $1.5 million, respectively. These notes are payable in less than one year and bear interest of 3.0 percent. The notes between NSP China and the Company eliminate in consolidation.
(11) Fair Value Measurements
The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2020 (dollar amounts in thousands):

| Level 1 |  | Level 2 |  | Level 3 |  |
| Quoted Prices in Active Markets for Identical Assets |  | Significant Other Observable Inputs |  | Significant Unobservable Inputs |  | Total
Investment securities - trading | $ | 1,035 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,035 |
Total assets measured at fair value on a recurring basis | $ | 1,035 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,035 |

19

Table of Contents
The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2019 (dollar amounts in thousands):

| Level 1 |  | Level 2 |  | Level 3 |  |
| Quoted Prices in Active Markets for Identical Assets |  | Significant Other Observable Inputs |  | Significant Unobservable Inputs |  | Total
Investment securities - trading | $ | 1,150 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,150 |
Total assets measured at fair value on a recurring basis | $ | 1,150 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,150 |

Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets.
For the six months ended June 30, 2020, and for the year ended December 31, 2019, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3).
The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying amount reflected on the condensed consolidated balance sheets for the revolving credit facility approximates fair value due to it being variable-rate debt. During the six months ended June 30, 2020 and 2019, we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.
(12) Revenue Recognition
Revenue Recognition
Net sales include products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue.
A reserve for product returns is recorded based upon historical experience and current trends. We allow independent Managers or Distributors to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive.
From time to time, our U.S. operations extend short-term credit associated with product promotions. In addition, for certain of our international operations, we offer credit terms consistent with industry standards within the country of operation.
Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent distributors. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent Managers and Distributors for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Payments for sales incentives and rebates are calculated monthly based upon qualifying sales.
Contract Liabilities - Customer Loyalty Programs
We record contract liabilities for loyalty point programs in deferred revenue. These programs are accounted for as a reduction in the transaction price and are generally recognized as points that are redeemed for additional products.
20

Table of Contents
The following table presents changes in these contract liability balances for the six-month period ended June 30, 2020 (U.S. dollars in thousands):

Outstanding at December 31, 2019 | $ | 955 |
Increase (decrease) attributed to: |
Customer loyalty net deferrals | 3,779 |
Customer loyalty redemptions | (3,830) |
Outstanding at June 30, 2020 | $ | 904 |

The table above excludes liability for sales returns, as they are insignificant.
Disaggregation of Revenue
Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category.
Practical Expedients and Exemptions
We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606.
We generally expense volume incentives when incurred because the amortization period would have been one year or less.
All of our contracts with customers have a duration of less than one year. The value of any unsatisfied performance obligations is insignificant.
21

Table of Contents
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management’s Discussion and Analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included in this report, as well as the consolidated financial statements, the notes thereto, and management’s discussion and analysis included in our Annual Report on Form 10-K for the year ended December 31, 2019, and our other reports filed since the date of such Form 10-K. During the second quarter of 2019, we realigned into geographic focused operating business segments across brands. The presentation of the comparative information has been recast to conform to the 2019 realignment.
OVERVIEW
We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent distributors who use the products themselves or resell them to consumers.
Our independent distributors market and sell our products to customers and sponsor other independent distributors who also market our products to customers. Our sales are highly dependent upon the number and productivity of our independent distributors. Growth in sales volume generally requires an increase in the productivity of our independent distributors and/or growth in the total number of independent distributors. We seek to motivate and provide incentives to our independent distributors by offering high quality products and providing independent distributors with product support, training seminars, sales conventions, travel programs and financial incentives.
In or about December 2019, a novel strain of coronavirus, SARS-CoV-2 "COVID-19", began aggressively spreading throughout the world, including all the primary markets where we conduct business. As COVID-19 has spread throughout the world, it has impacted our markets differently. Throughout our markets, governments issued orders to shelter in place and other restrictions that limited the ability of our Distributors to meet with consumers, which resulted in lower sales during the quarter. Although similar restrictions have been issued in our European markets, we experienced an increase in sales due to increased demand for nutritional supplements. However, there can be no assurance that demand for our products will not decrease in our European markets, particularly as restrictions on travel and gatherings adopted later in the first quarter, and continually evolving, limit the ability of our distributors to meet with consumers in such areas. While we are taking actions to mitigate the effects COVID-19 may have on the business, there can be no assurances that these actions will be sufficient to minimize its impact on the consolidated financial statement or material health of the Company. At this time, the duration of the business disruption and related financial impact cannot be reasonably estimated. An updated discussion of COVID-19's impact on the Company and other risk factors is included in Part II, Item 1A of this document.
In the second quarter of 2020, we experienced a decrease in our consolidated net sales of 3.8 percent (or 2.1 percent in local currencies) compared to the same period in 2019. Asia net sales decreased approximately 6.8 percent (or 4.4 percent in local currencies) compared to the same period in 2019. Europe net sales increased approximately 2.6 percent (or 4.1 percent in local currencies) compared to the same period in 2019. North America net sales decreased approximately 0.4 percent (or 0.2 percent in local currencies) compared to the same period in 2019. Latin America and Other net sales decreased approximately 21.7 percent (or 16.4 percent in local currencies) compared to the same period in 2019. The strengthening of the U.S. dollar versus the local currencies, primarily in our Asian, European and Latin America and Other markets, resulted in an approximate 2.1 percent, or $1.5 million, decrease of our net sales during the quarter.
Selling, general and administrative expenses during the three months ended June 30, 2020, decreased $2.5 million compared to the same period in 2019, and decreased as a percentage of net sales to 32.7 percent from 34.2 percent in 2019. The decrease in expenses was primarily the result of reduction in travel and customer event related costs due to COVID-19; and restructuring efforts implemented in prior periods in order to improve operating results.
We distribute our products to consumers through an independent sales force comprised of independent Managers and Distributors, many of whom also consume our products. Typically a person who joins our independent sales force begins as a Distributor. An independent Distributor may earn Manager status by attaining certain product sales levels. On a worldwide basis, active independent Managers were approximately 13,700 and 12,900 and active independent Distributors and customers were approximately 224,100 and 232,000 at June 30, 2020 and 2019, respectively.
As an international business, we have significant sales and costs denominated in currencies other than the U.S. Dollar. Sales in international markets denominated in foreign currencies are expected to continue to represent a substantial portion of
22

Table of Contents
our sales. Likewise, we expect foreign markets with functional currencies other than the U.S. Dollar will continue to represent a substantial portion of our overall sales and related operating expenses. Accordingly, changes in foreign currency exchange rates could materially affect sales and costs or the comparability of sales and costs from period to period as a result of translating foreign markets financial statements into our reporting currency.
RESULTS OF OPERATIONS
The following table summarizes our unaudited consolidated operating results from continuing operations in U.S. dollars and as a percentage of net sales for the three months ended June 30, 2020 and 2019 (dollar amounts in thousands):

| Three Months Ended June 30, 2020 |  |  |  | Three Months Ended June 30, 2019 |  |  |  | Change |  |
| Total dollars |  | Percent of net sales |  | Total dollars |  | Percent of net sales |  | Total dollars |  | Percentage
Net sales | $ | 87,286 |  |  | 100.0 | % |  | $ | 90,724 |  |  | 100.0 | % |  | $ | (3,438) |  |  | (3.8) | %
Cost of sales | 23,017 |  |  | 26.4 |  |  | 23,865 |  |  | 26.3 |  |  | (848) |  |  | (3.6) |
Gross profit | 64,269 |  |  | 73.6 |  |  | 66,859 |  |  | 73.7 |  |  | (2,590) |  |  | (3.9) |
Volume incentives | 29,165 |  |  | 33.4 |  |  | 31,302 |  |  | 34.5 |  |  | (2,137) |  |  | (6.8) |
SG&A expenses | 28,504 |  |  | 32.7 |  |  | 31,019 |  |  | 34.2 |  |  | (2,515) |  |  | (8.1) |
Operating income | 6,600 |  |  | 7.6 |  |  | 4,538 |  |  | 5.0 |  |  | 2,062 |  |  | 45.4 |
Other income, net | 1,509 |  |  | 1.7 |  |  | 306 |  |  | 0.3 |  |  | 1,203 |  |  | 393.1 |
Income before income taxes | 8,109 |  |  | 9.3 |  |  | 4,844 |  |  | 5.3 |  |  | 3,265 |  |  | 67.4 |
Provision for income taxes | 1,976 |  |  | 2.3 |  |  | 2,215 |  |  | 2.4 |  |  | (239) |  |  | (10.8) |
Net income | $ | 6,133 |  |  | 7.0 | % |  | $ | 2,629 |  |  | 2.9 | % |  | $ | 3,504 |  |  | 133.3 | %

The following table summarizes our unaudited consolidated operating results from continuing operations in U.S. dollars and as a percentage of net sales for the six months ended June 30, 2020 and 2019 (dollar amounts in thousands):

| Six Months Ended June 30, 2020 |  |  |  | Six Months Ended June 30, 2019 |  |  |  | Change |  |
| Total dollars |  | Percent of net sales |  | Total dollars |  | Percent of net sales |  | Total dollars |  | Percentage
Net sales | $ | 183,212 |  |  | 100.0 | % |  | $ | 181,996 |  |  | 100.0 | % |  | $ | 1,216 |  |  | 0.7 | %
Cost of sales | 47,698 |  |  | 26.0 |  |  | 47,294 |  |  | 26.0 |  |  | 404 |  |  | 0.9 |
Gross profit | 135,514 |  |  | 74.0 |  |  | 134,702 |  |  | 74.0 |  |  | 812 |  |  | 0.6 |
Volume incentives | 62,183 |  |  | 33.9 |  |  | 62,315 |  |  | 34.2 |  |  | (132) |  |  | (0.2) |
SG&A expenses | 59,569 |  |  | 32.5 |  |  | 64,871 |  |  | 35.6 |  |  | (5,302) |  |  | (8.2) |
Operating income | 13,762 |  |  | 7.5 |  |  | 7,516 |  |  | 4.1 |  |  | 6,246 |  |  | 83.1 |
Other income (loss), net | (901) |  |  | (0.5) |  |  | 258 |  |  | 0.1 |  |  | (1,159) |  |  | (449.2) |
Income before income taxes | 12,861 |  |  | 7.0 |  |  | 7,774 |  |  | 4.3 |  |  | 5,087 |  |  | 65.4 |
Provision for income taxes | 3,722 |  |  | 2.0 |  |  | 3,416 |  |  | 1.9 |  |  | 306 |  |  | 9.0 |
Net income | $ | 9,139 |  |  | 5.0 | % |  | $ | 4,358 |  |  | 2.4 | % |  | $ | 4,781 |  |  | 109.7 | %

23

Table of Contents
Net Sales
International operations have provided, and are expected to continue to provide, a significant portion of our total net sales. As a result, total net sales will continue to be affected by fluctuations in the U.S. dollar against foreign currencies. In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, in addition to comparing the percent change in net sales from one period to another in U.S. dollars, we present net sales excluding the impact of foreign exchange fluctuations. We compare the percentage change in net sales from one period to another period by excluding the effects of foreign currency exchange as shown below. Net sales excluding the impact of foreign exchange fluctuations is not a U.S. GAAP financial measure and removes from net sales in U.S. dollars the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries, by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period. We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. However, net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. Throughout the last five years, foreign currency exchange rates have fluctuated significantly. See Item 3. Quantitative and Qualitative Disclosures about Market Risk.
The following table summarizes the changes in net sales by operating segment with a reconciliation to net sales excluding the impact of currency fluctuations for the three months ended June 30, 2020 and 2019 (dollar amounts in thousands):

| Net Sales by Operating Segment |  |  |  |  |  |  |  |
| Three Months Ended June 30, 2020 |  | Three Months Ended June 30, 2019 |  | Percent Change |  | Impact of Currency Exchange |  | Percent Change Excluding Impact of Currency
Asia | $ | 32,757 |  |  | $ | 35,162 |  |  | (6.8) | % |  | $ | (872) |  |  | (4.4) | %
Europe | 15,465 |  |  | 15,075 |  |  | 2.6 |  |  | (232) |  |  | 4.1 |
North America | 34,471 |  |  | 34,620 |  |  | (0.4) |  |  | (92) |  |  | (0.2) |
Latin America and Other | 4,593 |  |  | 5,867 |  |  | (21.7) |  |  | (311) |  |  | (16.4) |
| $ | 87,286 |  |  | $ | 90,724 |  |  | (3.8) | % |  | $ | (1,507) |  |  | (2.1) | %

The following table summarizes the changes in net sales by operating segment with a reconciliation to net sales excluding the impact of currency fluctuations for the six months ended June 30, 2020 and 2019 (dollar amounts in thousands):

| Net Sales by Operating Segment |  |  |  |  |  |  |  |
| Six Months Ended June 30, 2020 |  | Six Months Ended June 30, 2019 |  | Percent Change |  | Impact of Currency Exchange |  | Percent Change Excluding Impact of Currency
Asia | $ | 63,715 |  |  | $ | 68,758 |  |  | (7.3) | % |  | $ | (1,954) |  |  | (4.5) | %
Europe | 36,092 |  |  | 30,672 |  |  | 17.7 |  |  | (429) |  |  | 19.1 |
North America | 73,228 |  |  | 71,143 |  |  | 2.9 |  |  | (115) |  |  | 3.1 |
Latin America and Other | 10,177 |  |  | 11,423 |  |  | (10.9) |  |  | (414) |  |  | (7.3) |
| $ | 183,212 |  |  | $ | 181,996 |  |  | 0.7 | % |  | $ | (2,912) |  |  | 2.3 | %

Consolidated net sales for the three and six months ended June 30, 2020, were $87.3 million and $183.2 million, respectively, compared to $90.7 million and $182.0 million for the same period in 2019, which represents a decrease of 3.8 percent and an increase of 0.7 percent, respectively. The decrease for the three months ended June 30, 2020, was primarily related to declines in the Asia and Latin America and Other markets. Declines in these markets were partially offset by product sales growth in the Europe market. The increase for the six months ended June 30, 2020, was primarily related to product sales growth in the Europe and North America markets. Growth in these markets was offset by declines in the Asia and Latin America and Other markets. Excluding the unfavorable impact of foreign currency exchange rate fluctuations, consolidated net
24

Table of Contents
sales for the three and six months ended June 30, 2020, decreased 2.1 percent and increased 2.3 percent, respectively, from the same periods in 2019.
Asia
Net sales related to Asia for the three and six months ended June 30, 2020, were $32.8 million and $63.7 million, respectively, compared to $35.2 million and $68.8 million for the same periods in 2019, or decreases of 6.8 percent and 7.3 percent. In local currency, net sales for the three and six months ended June 30, 2020, decreased 4.4 percent and 4.5 percent, respectively, compared to the same periods in 2019. Net sales for the Asia business is further discussed in the South Korea, Japan and China commentary below. Active independent Managers within Asia totaled approximately 2,900 and 3,000 at June 30, 2020 and 2019, respectively. Active independent Distributors and customers within Asia totaled approximately 34,500 and 38,300 at June 30, 2020 and 2019, respectively.
Notable activity in the following markets contributed to the results of Asia:
In our South Korea market, net sales decreased $4.5 million and $6.6 million, or decreased 23.6 percent and 17.6 percent, for the three and six months ended June 30, 2020, respectively, compared to the same periods in 2019. In local currency, net sales for the three and six months ended June 30, 2020, decreased 20.0 percent and 13.2 percent, respectively, compared to the same periods in 2019. The decrease in net sales was the result of restrictions in the market due to COVID-19, which decreased distributor meetings and sales activity.
In our Japan market, net sales increased $0.4 million and $0.3 million, or 6.1 percent and 2.3 percent, for the three and six months ended June 30, 2020, respectively, compared to the same periods in 2019. In local currencies, net sales for the three and six months ended June 30, 2020, increased 3.9 percent and 0.7 percent, respectively, compared to the same periods in 2019. We attribute the growth in net sales primarily to product promotions intended to stimulate activity which had a positive impact on market sales volume.
In our China market, net sales increased $2.2 million and $1.5 million, or 33.9 percent and 11.7 percent, for the three and six months ended June 30, 2020, respectively, compared to the same periods in 2019. In local currencies, net sales for the three and six months ended June 30, 2020, increased 38.6 percent and 15.4 percent, respectively, compared to the same periods in 2019. Although growth has been impacted by current market conditions, China continues to show local currency growth primarily due to initiatives designed to increase independent service providers’ engagement levels and gain market share.
Europe
Net sales related to Europe for the three and six months ended June 30, 2020, were $15.5 million and $36.1 million, respectively, compared to $15.1 million and $30.7 million for the same periods in 2019, or increases of 2.6 percent and 17.7 percent. In local currency, net sales for the three and six months ended June 30, 2020, increased 4.1 percent and 19.1 percent, respectively, compared to the same periods in 2019. The functional currency for many of these markets is the U.S. Dollar which reduces the effect from foreign currency fluctuations. Fluctuations in foreign exchange rates had a $0.2 million and $0.4 million unfavorable impact on net sales for the three and six months ended June 30, 2020, respectively. Net sales increased primarily as a result of the relative stabilization of the Russian ruble against the U.S. dollar and product promotions that have improved distributor engagement. Active independent Managers within Europe totaled approximately 4,900 and 4,000 at June 30, 2020 and 2019, respectively. Active independent Distributors and customers within Europe totaled approximately 88,800 and 85,200 at June 30, 2020 and 2019, respectively.
North America
Net sales related to North America for the three and six months ended June 30, 2020, were $34.5 million and $73.2 million, respectively, compared to $34.6 million and $71.1 million for the same periods in 2019, or a decrease of 0.4 percent and an increase of 2.9 percent. In local currency, net sales for the three and six months ended June 30, 2020, decreased 0.2 percent and increased 3.1 percent, respectively, compared to the same periods in 2019. Net sales for the North America business are further discussed in United States commentary below. Active independent Managers within North America totaled approximately 4,700 and 4,700 at June 30, 2020 and 2019, respectively. Active independent Distributors and customers within North America totaled approximately 76,700 and 78,400 at June 30, 2020 and 2019, respectively.
Notable activity in the following markets contributed to the results of North America:
25

Table of Contents
In the United States, net sales decreased $46,000 and increased $1.8 million, or 0.1 percent and 2.8 percent, for the three and six months ended June 30, 2020, respectively, compared to the same periods in 2019. The year-to-date increase in the market is mainly due to several factors including, rebranding and rebuilding efforts of the Nature's Sunshine brand and Distributor tools in the U.S., an increase in demand for nutritional supplements in the U.S. in the wake of the COVID-19 pandemic and the launch of our new qemp Inc. CBD product brand. There is no guarantee that the results seen in the U.S. during first and second quarters of 2020 will continue into the third quarter due to the COVID-19 situation in the U.S., among other factors.
Latin America and Other
Net sales related to Latin America and Other markets for the three and six months ended June 30, 2020, were $4.6 million and $10.2 million, respectively, compared to $5.9 million and $11.4 million for the same periods in 2019, or decreases of 21.7 percent and 10.9 percent. In local currency, net sales for the three and six months ended June 30, 2020, decreased 16.4 percent and 7.3 percent, respectively, compared to the same periods in 2019. Currency devaluation had a $0.3 million and $0.4 million unfavorable impact on net sales for the three and six months ended June 30, 2020, respectively. The decline in the market is mainly due to decreases in Distributor retention and average purchase size as well as restrictions in the market due to COVID-19, which further decreased distributor meetings and sales activity. Active independent Managers totaled approximately 1,200 and 1,200 at June 30, 2020 and 2019, respectively. Active independent Distributors and customers totaled approximately 24,100 and 30,100 at June 30, 2020 and 2019, respectively.
Further information related to our Asia, Europe, North America, and Latin America and Other business segments is set forth in Note 7 to the Unaudited Condensed Consolidated Financial Statements in Part 1, Item 1 of this report.
Cost of Sales
Cost of sales as a percent of net sales was 26.4 percent and 26.0 percent for the three and six months ended June 30, 2020, compared to 26.3 percent and 26.0 percent for the same periods in 2019. The modest increase in cost of sales percentage is due to unfavorable changes in market mix, among other factors.
Volume Incentives
Volume incentives expense as a percent of net sales was 33.4 percent and 33.9 percent for the three and six months ended June 30, 2020, respectively, compared to 34.5 percent and 34.2 percent for the same periods in 2019. These payments are designed to provide incentives for reaching higher sales levels. Volume incentives vary slightly, on a percentage basis, by product due to pricing policies and commission plans in place in our various operations. We do not pay volume incentives in China, instead we pay independent service fees, which are included in selling, general and administrative expenses. Volume incentives as a percentage of net sales can fluctuate based on promotional activity and mix of sales by market. The decrease in volume incentives as a percent of net sales for the six months ended June 30, 2020 is primarily due to changes in market mix, reflecting growth in markets where volume incentives as a percentage of net sales are lower than the consolidated average, and the growth in NSP China.
Selling, General and Administrative
Selling, general and administrative expenses represent operating expenses, components of which include labor and benefits, sales events, professional fees, travel and entertainment, marketing, occupancy costs, communications costs, bank fees, depreciation and amortization, independent services fees paid in China, and other miscellaneous operating expenses.
Selling, general and administrative expenses decreased by $2.5 million and $5.3 million, respectively, to $28.5 million and $59.6 million for the three and six months ended June 30, 2020, respectively, compared to the same periods in 2019. Selling, general and administrative expenses were 32.7 percent and 32.5 percent of net sales for the three and six months ended June 30, 2020, respectively, compared to 34.2 percent and 35.6 percent for the same periods in 2019. The decrease in selling, general and administrative expenses was primarily related to a reduction of headcount in the U.S. and Latin America as a result of restructuring, decrease in travel and event related costs and other cost reductions, net of any incremental costs associated with COVID-19.
26

Table of Contents
Other Income (Loss), Net
Other income (loss), net, for the three and six months ended June 30, 2020, were gains of $1.5 million and losses of $0.9 million, respectively, compared to gains of $0.3 million and $0.3 million during the same periods in 2019, respectively. Other income (loss), for the three and six months ended June 30, 2020 primarily consisted of foreign exchange gains and losses as a result of net changes in foreign currencies primarily in Asia, Europe and Latin America.
Income Taxes
For the three months ended June 30, 2020 and 2019, our provision for income taxes, as a percentage of income before income taxes was 24.4 percent and 45.7 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2020 and 2019, our provision for income taxes, as a percentage of income before income taxes was 28.9 percent and 43.9 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent.
The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2020, was primarily attributed to transfer pricing adjustments and current year foreign losses that presently do not provide future tax benefit, as well as net unfavorable foreign tax related items.
The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2019, was primarily attributed to foreign losses during those periods that were not expected to provide future tax benefit, as well as net unfavorable foreign tax related items.
The difference between the effective tax rate for the three and six months ended June 30, 2020 compared to June 30, 2019 is primarily caused by the increase in income. This increase to income causes items such as foreign losses and unfavorable tax adjustments to have a lesser impact on the effective tax rate.
Our U.S. federal income tax returns for 2016 through 2018 are open to examination for federal tax purposes. We have several foreign tax jurisdictions that have open tax years from 2014 through 2019.
As of June 30, 2020 and December 31, 2019, we had had accrued $1.4 million and $1.5 million, respectively, related to unrecognized tax positions.
Product Categories
Our line of over 700 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. We purchase herbs and other raw materials in bulk and, after rigorous quality control testing, we formulate, encapsulate, tablet or concentrate them, label and package them for shipment. Most of our products are manufactured at our facility in Spanish Fork, Utah. Contract manufacturers produce some of our products in accordance with our specifications and standards. We have implemented stringent quality control procedures to verify that our contract manufacturers have complied with our specifications and standards.
See Note 7, Segment Information, for a summary of the U.S. dollar amounts from the sale of general health, immune, cardiovascular, digestive, personal care and weight management products for the three and six months ended June 30, 2020 and 2019, by business segment.
Distribution and Marketing
Our independent distributors, also known as Managers and Distributors, market our products to customers through direct selling techniques and sponsor other independent distributors who also market our products to customers. We seek to motivate and provide incentives to our independent distributors by offering high quality products and providing independent distributors with product support, training seminars, sales conventions, travel programs and financial incentives.
Our products sold in the United States are shipped directly from our manufacturing and warehouse facilities located in Spanish Fork, Utah, as well as from our regional warehouses located in Georgia, Ohio and Texas. Many of our international operations maintain warehouse facilities and inventory to supply their independent Managers, Distributors and customers. However, in foreign markets where we do not maintain warehouse facilities, we have contracted with third-parties to distribute our products and provide support services to our independent sales force of independent Managers and Distributors.
27

Table of Contents
As of June 30, 2020, we had approximately 224,100 “active independent Distributors and customers” (as defined below). A person who joins our independent sales force begins as an independent distributor. Many independent distributors sell our products on a part-time basis to friends or associates or use the products themselves. An independent distributor may earn Manager status by attaining certain product sales levels. As of June 30, 2020, we had approximately 13,700 “active independent Managers” (as defined below) worldwide. In many of our markets, our independent Managers and Distributors are primarily retailers of our products, including practitioners, proprietors of retail stores and other health and wellness specialists.
In the United States, we generally sell our products on a cash or credit card basis. From time to time, our U.S. operations extend short-term credit associated with product promotions. For certain of our international operations, we use independent distribution centers and offer credit terms that are generally consistent with industry standards within each respective country.
We pay sales commissions, or “volume incentives” to our independent Managers and Distributors based upon their own product sales and the product sales of their sales organization. As an exception, in NSP China, we do not pay volume incentives; rather, we pay independent service fees, which are included in selling, general and administrative expense. These volume incentives are recorded as an expense in the year earned. The amounts of volume incentives that we expensed during the quarters ended June 30, 2020 and 2019, are set forth in the Condensed Consolidated Financial Statements in Item 1 of this report. In addition to the opportunity to receive volume incentives, independent Managers who attain certain levels of monthly product sales are eligible for additional incentive programs including automobile allowances, sales convention privileges and travel awards.
Distributor Information
Our revenue is highly dependent upon the number and productivity of our independent Managers and Distributors. Growth in sales volume requires an increase in the productivity and/or growth in the total number of independent Managers and Distributors.
Within the Company, there are a number of different distributor compensation plans and qualifications, which generate active independent Managers and Distributors with different sales values in our different business segments. Within Synergy WorldWide, the sales qualifications required for active independent Managers and Distributors varies by market according to local economic factors. As sales grow in markets with higher qualification values, and decline in those with lower qualification values, the resultant mix change influences the active counts for independent Managers and Distributors. As a result, from time-to-time, changes in overall active counts for independent Managers and Distributors may not be indicative of actual sales trends for the segment.
In China, we do not sell our products through Managers and Distributors, but rather through independent service providers who are compensated for marketing, sales support, and other services.
The following table provides information concerning the number of total independent Managers, Distributors and customers by segment, as of the dates indicated:
Total Managers, Distributors and Customers by Segment as of June 30,

| 2020 |  |  |  | 2019 |  |
| Distributors & Customers |  | Managers |  | Distributors & Customers |  | Managers
Asia | 87,400 |  |  | 2,900 |  |  | 87,500 |  |  | 3,000 |
Europe | 199,800 |  |  | 4,900 |  |  | 174,800 |  |  | 4,000 |
North America | 160,400 |  |  | 4,700 |  |  | 162,800 |  |  | 4,700 |
Latin America and Other | 66,600 |  |  | 1,200 |  |  | 64,100 |  |  | 1,200 |
| 514,200 |  |  | 13,700 |  |  | 489,200 |  |  | 12,900 |

“Total Managers” includes independent Managers under our various compensation plans that have achieved and maintained specified and personal groups sale volumes as of the date indicated. To maintain Manager status, an individual must continue to meet certain product sales volume levels. As such, all Managers are considered to be “Active Managers”.
“Total Distributors and customers” includes our independent Distributors and customers who have purchased products directly from the Company for resale and/or personal consumption during the previous twelve months ended as of the date
28

Table of Contents
indicated. This includes independent Manager, Distributor and customer accounts that may have become inactive since such respective dates.
The following table provides information concerning the number of active Distributors and customers by segment, as of the dates indicated:
Active Distributors and Customers by Segment as of June 30,

| 2020 |  |  |  | 2019 |  |
| Distributors & Customers |  | Managers |  | Distributors & Customers |  | Managers
Asia | 34,500 |  |  | 2,900 |  |  | 38,300 |  |  | 3,000 |
Europe | 88,800 |  |  | 4,900 |  |  | 85,200 |  |  | 4,000 |
North America | 76,700 |  |  | 4,700 |  |  | 78,400 |  |  | 4,700 |
Latin America and Other | 24,100 |  |  | 1,200 |  |  | 30,100 |  |  | 1,200 |
| 224,100 |  |  | 13,700 |  |  | 232,000 |  |  | 12,900 |

“Active Distributors and customers” include our independent Distributors and customers who have purchased products directly from the Company for resale and/or personal consumption during the previous three months ended as of the date indicated.
The following table provides information concerning the number of new independent Managers, Distributors and customers by segment, for the periods indicated:
New Managers, Distributors and Customers by Segment for the Three Months Ended June 30,

| 2020 |  |  |  | 2019 |  |
| New Distributors & Customers |  | New Managers |  | New Distributors & Customers |  | New Managers
Asia | 13,700 |  |  | 700 |  |  | 16,400 |  |  | 700 |
Europe | 23,800 |  |  | 400 |  |  | 17,500 |  |  | 300 |
North America | 16,100 |  |  | 500 |  |  | 17,200 |  |  | 400 |
Latin America and Other | 6,700 |  |  | 100 |  |  | 7,900 |  |  | 100 |
| 60,300 |  |  | 1,700 |  |  | 59,000 |  |  | 1,500 |

“New Managers” includes independent Managers under our various compensation plans that first achieved the rank of Manager during the previous three months ended as of the date indicated.
“New Distributors and Customers” include our independent Distributors and customers who have made their initial product purchase directly from the Company for resale and/or personal consumption during the previous three months ended as of the date indicated.
The following table provides information concerning the number of new Managers, Distributors and customers by segment, for the periods indicated:
29

Table of Contents
New Managers, Distributors and Customers by Segment for the Six Months Ended June 30,

| 2020 |  |  |  | 2019 |  |
| New Distributors & Customers |  | New Managers |  | New Distributors & Customers |  | New Managers
Asia | 60,700 |  |  | 2,500 |  |  | 61,600 |  |  | 2,600 |
Europe | 87,800 |  |  | 1,500 |  |  | 69,200 |  |  | 1,200 |
North America | 65,400 |  |  | 2,100 |  |  | 63,500 |  |  | 1,600 |
Latin America and Other | 33,800 |  |  | 500 |  |  | 27,700 |  |  | 500 |
| 247,700 |  |  | 6,600 |  |  | 222,000 |  |  | 5,900 |

“New Managers” includes independent Managers under our various compensation plans that first achieved the rank of Manager during the previous twelve months ended as of the date indicated.
“New Distributors and Customers” include our independent Distributors and customers who have made their initial product purchase directly from the Company for resale and/or personal consumption during the previous twelve months ended as of the date indicated.
LIQUIDITY AND CAPITAL RESOURCES
Our principal use of cash is to pay for operating expenses, including volume incentives, inventory and raw material purchases, capital assets and funding of international expansion. As of June 30, 2020, working capital was $72.1 million, compared to $54.8 million as of December 31, 2019. At June 30, 2020, we had $70.3 million in cash, of which $24.4 million was held in the U.S. and $45.9 million was held in foreign markets and may be subject to various withholding taxes and other restrictions related to repatriation before becoming available to be used along with the normal cash flows from operations to fund any unanticipated shortfalls in future cash flows.
Our net consolidated cash inflows (outflows) are as follows (in thousands):

| Six Months Ended June 30, |  |
| 2020 |  | 2019
Operating activities | $ | 14,420 |  |  | $ | (1,144) |
Investing activities | (2,210) |  |  | (2,774) |
Financing activities | 5,164 |  |  | (193) |

Operating Activities
For the six months ended June 30, 2020, operating activities provided cash of $14.4 million, compared to using cash of $1.1 million in the same period in 2019. Operating cash flows increased primarily due to past and ongoing efforts to reduce operating costs and increase profitability and working capital.
Investing Activities
For the six months ended June 30, 2020, investing activities used $2.2 million, compared to $2.8 million for the same period in 2019. Capital expenditures related to the purchase of equipment, computer systems and software for the six months ended June 30, 2020 and 2019, were $2.2 million and $2.8 million, respectively.
Financing Activities
For the six months ended June 30, 2020, financing activities provided $5.2 million, compared to using $0.2 million in cash for the same period in 2019. Financing cash flows increased primarily due proceeds from a loan, noted below.
On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 11, 2020 the credit agreement was amended to extend the term to mature on July 1, 2023. The amendment also allows for additional borrowings of $15.0 million or up to three separate increases of no less than $5.0 million each. We pay interest on any borrowings under the Credit Agreement, which through June 10, 2020, was
30

Table of Contents
at LIBOR plus 1.25 percent (3.05 percent as of December 31, 2019), and an annual commitment fee of 0.2 percent on the unused portion of the commitment. Interest under the amended Credit Agreement is at LIBOR, or the Index floor of 0.75 percent, plus 2.25 percent (3.00 percent as of June 30, 2020), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. We are required to settle our net borrowings under the Credit Agreement only upon maturity, and as a result, have classified prior outstanding borrowings as non-current on our condensed consolidated balance sheet. At June 30, 2020, there was no outstanding balance under the Credit Agreement.
The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, and merger, consolidation and the transfer of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable balance, inventory balance and other assets. As of June 30, 2020, we were in compliance with the debt covenants set forth in the Credit Agreement.
On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million, that matures sixty months from the Base Date, which must not be later than April 30, 2021 (the "Capital Credit Agreement"). We pay interest on any borrowings under the Capital Credit Agreement at the Indicative Index plus 2.8 percent (3.5 percent as of June 30, 2020). We are required to settle our borrowings under the Capital Credit Agreement in sixty monthly payments, each equal to 1.8 percent of the loan amount. The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. After inception and as of June 30, 2020, there was no outstanding balance under the Capital Credit Agreement.
On April 14, 2020, we obtained a loan (the “Loan”) from Bank of America, B.A. in the amount of $5.4 million under the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The PPP is a loan designed to provide an incentive for qualifying businesses to maintain their employees on the payroll despite significant economic uncertainty. We applied to receive the Loan based on the significant economic uncertainty facing the Company in the U.S. and globally.
The Loan matures on April 14, 2022 and bears interest at a rate of 1.00 percent per annum, payable monthly commencing on November 15, 2020. We may prepay the Note at any time prior to maturity with no prepayment penalties. The principal amount of the Loan and accrued interest are eligible for forgiveness after either eight weeks or 26 weeks if we use the Loan proceeds for qualifying expenses, including payroll, rent, and utilities during the eight week period commencing on the date the Loan has been advanced. The amount of the Loan eligible for forgiveness will be reduced to the extent that we have (i) terminated full-time employees during the period commencing February 15, 2020 and ending April 26, 2020 and (ii) reduced salaries (beyond a statutorily prescribed threshold) during the eight week period commencing on the date the Loan has been advanced. We will be obligated to repay any portion of the principal amount of the Note that is not forgiven, together with accrued interest thereon at the rate set forth above until such unforgiven portion is paid in full. As of June 30, 2020, there was $5.4 million outstanding under the PPP, $2.4 million of which was classified as current.
We believe that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund our normal operating needs, including capital expenditures, on both a short- and long-term basis should disruptions related to COVID-19 be minimized. While we are taking actions to mitigate the effects COVID-19 may have on the business, there can be no assurances that these actions will be sufficient to minimize its impact on the consolidated financial statement or material health of the Company. For example, if a closure of our manufacturing facility were to occur, it could have a significant impact of the financial health of the Company. At this time, the duration of the business disruption and related financial impact cannot be reasonably estimated. An updated discussion of COVID-19's impact on the Company and other risk factors is included in Part II, Item 1A of this document.
In addition, other things such as a prolonged economic downturn, a decrease in demand for our products, an unfavorable settlement of our unrecognized tax positions or non-income tax contingencies could adversely affect our long-term liquidity.
OFF-BALANCE SHEET ARRANGEMENTS
We have no off-balance sheet arrangements.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our consolidated financial statements have been prepared in accordance with U.S. GAAP and form the basis for the following discussion and analysis on critical accounting policies and estimates. The preparation of these financial statements
31

Table of Contents
requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a regular basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates and those differences could have a material effect on our financial position and results of operations. We have discussed the development, selection and disclosure of these estimates with the Board of Directors and our Audit Committee.
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2019. We believe the critical accounting policies and estimates described below reflect our more significant estimates and assumptions used in the preparation of the consolidated financial statements. The impact and any associated risks on our business that are related to these policies are also discussed throughout this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” where such policies affect reported and expected financial results.
Revenue Recognition
Our revenue recognition practices are discussed in Note 12, “Revenue Recognition,” to our Condensed Consolidated Financial Statements in Item 1, Part 1 of this report.
Inventories
Inventories are adjusted to lower of cost and net realizable value, using the first-in, first-out method. The components of inventory cost include raw materials, labor and overhead. To estimate any necessary adjustments, various assumptions are made in regard to excess or slow-moving inventories, non-conforming inventories, expiration dates, current and future product demand, production planning and market conditions. If future demand and market conditions are less favorable than our assumptions, additional inventory adjustments could be required.
Incentive Trip Accrual
We accrue for expenses associated with our direct sales program, which rewards independent Managers and Distributors with paid attendance for incentive trips, including our conventions and meetings. Expenses associated with incentive trips are accrued over qualification periods as they are earned. We specifically analyze incentive trip accruals based on historical and current sales trends as well as contractual obligations when evaluating the adequacy of the incentive trip accrual. Actual results could generate liabilities more or less than the amounts recorded.
Contingencies
We are involved in certain legal proceedings. When a loss is considered probable in connection with litigation or non-income tax contingencies and when such loss can be reasonably estimated with a range, we record our best estimate within the range related to the contingency. If there is no best estimate, we record the minimum of the range. As additional information becomes available, we assess the potential liability related to the contingency and revise the estimates. Revision in estimates of the potential liabilities could materially affect our results of operations in the period of adjustment. Our contingencies are discussed in further detail in Note 10, “Commitments and Contingencies”, to the Notes of our Condensed Consolidated Financial Statements, of Item 1, Part 1 of this report.
Income Taxes
Our provision for income taxes, deferred tax assets and liabilities and contingent reserves reflect management’s best assessment of estimated future taxes to be paid. We are subject to income taxes in both the United States and numerous foreign jurisdictions. Significant judgments and estimates are required in determining our consolidated provision for income taxes.
Deferred income taxes arise from temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating our ability to recover our deferred tax assets, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. In projecting future taxable income, we develop assumptions including the amount of future state, federal and foreign pretax operating income, the reversal of temporary differences, and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income, and are consistent with the plans and estimates that we are using to manage the underlying businesses.
32

Table of Contents
Valuation allowances are recorded as reserves against net deferred tax assets by us when it is determined that net deferred tax assets are not likely to be realized in the foreseeable future.
Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on our results of operations, cash flows or financial position.
The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized.
Item 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We conduct business in several countries and intend to grow our international operations. Net sales, operating income and net income are affected by fluctuations in currency exchange rates, interest rates and other uncertainties inherent in doing business and selling product in more than one currency. In addition, our operations are exposed to risks associated with changes in social, political and economic conditions inherent in international operations, including changes in the laws and policies that govern international investment in countries where we have operations, as well as, to a lesser extent, changes in U.S. laws and regulations relating to international trade and investment. For further information, see Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2019.
Item 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) are designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2020. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2020, at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There were no other changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended June 30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
33

Table of Contents
PART II OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
None.
Item 1A. RISK FACTORS
In addition to the information set forth in this report, you should carefully consider the risks discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, which could have a material adverse effect on our business or consolidated financial statements, results of operations, and cash flows. Additional risks not currently known, or risks that are currently believed to be not material, may also impair business operations. There have been no material changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2019.
The ongoing outbreak of coronavirus and the responses thereto around the world could adversely impact our business and operating results.
In or about December 2019, a novel strain of coronavirus, SARS-CoV-2, began aggressively spreading throughout the world, including all the primary markets where we conduct business. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the President of the United States declared the COVID-19 pandemic a national emergency. Governments around the world have issued, and others in the future may issue, orders for their citizens to shelter-in-place to control the spread of COVID-19. Such orders, restrictions and recommendations, and the anticipation that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed “essential,” work stoppages, limitations on the number of people allowed to gather in one location, slowdowns and delays in world-wide supply chains, work-from-home policies, travel restrictions and cancellation of events, among other effects that have led to record declines in stock prices and oil prices, as well as unprecedented high levels of unemployment. These orders and restrictions have limited the ability of our Distributors to meet consumers and resulted in lower sales in Asia. Similar orders and restrictions in other regions of the world may also limit the ability of our Distributors to meet with consumers and may result in lower sales in those regions.
The duration and extent of COVID-19's impact on our business are difficult to assess or predict. The widespread pandemic has resulted and may continue to result for an extended period, in significant disruption of global financial markets, reducing our ability to access capital, repatriate funds from foreign markets, which would negatively affect our liquidity. Further, quarantines or government reaction or shutdowns for COVID-19 could disrupt or halt our operations and harm our business, financial condition and results of operations. Our manufacturing personnel and other employees could also be affected by COVID-19, potentially reducing their availability, and large spread outbreak of COVID-19 among our manufacturing or supply-chain employees could disrupt or halt our operations. Further, restrictions on gatherings of individuals may limit the ability of our independent distributors to sell our products. Additionally, the procedures we take to mitigate the effect of COVID-19 on our workforce could reduce the efficiency of our operations, increase our opersting costs or prove insufficient.
Cybersecurity risks and the failure to maintain the integrity of data could expose us to data loss, litigation and liability, which could adversely affect our results of operations and financial condition.
We collect and retain large volumes of data from employees and independent distributors, including credit card numbers and other personally identifiable information, for business purposes, including transactional and promotional purposes. Our various information technology systems enter, process, summarize and report such data. The integrity and protection of this data are critical to our business. We are subject to significant security and privacy regulations, as well as requirements imposed by the credit card industry.
Similarly, a failure to adhere to the payment card industry’s data security standards could cause us to incur penalties from payment card associations, termination of our ability to accept credit or debit card payments, litigation and adverse publicity, any of which could have a material adverse effect on our business and financial condition.
Maintaining compliance with these evolving regulations and requirements could be difficult and may increase costs. In addition, a penetrated or compromised data system or the intentional, inadvertent or negligent release or disclosure of data could result in theft, loss or fraudulent or unlawful use of company, employee, distributor or guest data which could adversely affect our reputation, disrupt our operations, or result in remedial and other costs, fines or lawsuits, which could have a material adverse effect on our results of operations and financial condition. Although we take measures to protect the security, integrity
34

Table of Contents
and confidentiality of our data systems, we experience cyber-attacks of varying degrees and types on a regular basis. Our infrastructure may be vulnerable to these attacks, and in some cases, it could take time to discover them. Our security measures may also be breached due to employee error or malfeasance, system errors or otherwise. For various reasons or circumstances, our employees may work remotely from time to time. For example, many of our employees have worked remotely in response to the spread of the COVID-19 pandemic. During such times, remote access heightens the risk of a cyber-attack. Additionally, outside parties may attempt to fraudulently induce employees, users, or customers to disclose sensitive information to gain access to our data or our users’ or customers’ data. Any such breach or unauthorized access could result in the unauthorized disclosure, misuse or loss of sensitive information and lead to significant legal and financial exposure, regulatory inquiries or investigations, loss of confidence by our sales force, disruption of our operations and damage to our reputation. These risks are heightened as we work with third-party partners and as our sales force uses social media, as the partners and social media platforms could be vulnerable to the same types of breaches.
Our manufacturing activity is subject to certain risks.
We manufacture a significant portion of the products sold at our manufacturing facility located in Spanish Fork, Utah. As a result, we are dependent upon the uninterrupted and efficient operation of our manufacturing facility in Spanish Fork and our distribution facilities throughout the country. Our manufacturing facilities and distribution facilities are subject to the risk of catastrophic loss due to, among other things, earthquake, fire, flood, epidemic, terrorism or other natural or man-made disasters, as well as the occurrence of significant equipment failures. If any of these facilities were to experience a catastrophic loss, it would be expected to disrupt our operations and could have a material adverse effect on our results of operations and financial condition. We source many of our ingredients and some of our finished products through third-party suppliers. If any of our third-party suppliers were to suffer a catastrophic loss, it would cause delays in our manufacturing and could have a material effect on our results of operations and financial condition.
As the primary manufacturer of our own products, we are subject to FDA regulations on GMPs, which require us to maintain good manufacturing processes, including ingredient identification, manufacturing controls and record keeping. Compliance with these regulations has increased and may further increase our cost of manufacturing products. Our results of operations and financial condition could be materially adversely affected if regulatory authorities make determinations that we are not in compliance with FDA regulations on GMPs. A finding of noncompliance may result in administrative warnings, penalties or actions impacting our ability to continue selling certain products, which could have a material adverse effect on our results of operations and financial condition.
In addition, we contract with third-party manufacturers to produce some of our vitamins, mineral and other nutritional supplements, personal care products and certain other miscellaneous products in accordance with our specifications and standards. These contract manufacturers are subject to the same risks as our manufacturing facility as noted above. In addition, while we have implemented stringent quality control procedures to verify that our contract manufacturers comply with our specifications and standards, we do not have full control over their manufacturing activities. Significant delays and defects in our products resulting from the activities of our contract manufacturers may have a material adverse effect on our results of operations and financial condition.
We may be adversely affected by changes to our independent distributor compensation plans.
We modify components of our compensation plans from time to time to keep them competitive and attractive to existing and potential independent distributors, to address changing market dynamics, to provide incentives to our independent distributors that we believe will help grow our business, to conform to local regulations and to address other business related considerations. In May 2020, we announced that we will be making significant changes to our compensation plan. It is difficult to predict how such changes will be viewed by our independent distributors and whether such changes will achieve their desired results. Such changes could result in unintended or unforeseen negative economic and non-economic consequences to our business, such as higher than anticipated costs or difficulty in attracting and retaining independent distributors, either of which could have a material adverse effect on our results of operations and financial condition.
We may not be entitled to forgiveness of our recently received PPP Loan, and our application for the PPP Loan could in the future be determined to have been impermissible or could result in damage to our reputation.
On April 14, 2020 we received proceeds of $5.4 million from a loan under the Paycheck Protection Program of the CARES Act, a portion of which may be forgiven, which we intend to use to retain current employees, maintain payroll and make lease and utility payments. The PPP Loan matures on April 14, 2022 and bears annual interest at a rate of 1.0%. Commencing November 14, 2020, we are required to pay the lender equal monthly payments of principal and interest as required to fully amortize by April 21, 2022 any principal amount outstanding on the PPP Loan as of October 14, 2020. A
35

Table of Contents
portion of the PPP Loan may be forgiven by the SBA upon our application beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the eight week period beginning on the date of loan approval. Not more than 25% of the forgiven amount may be for non-payroll costs. The amount of the PPP Loan eligible to be forgiven is limited because of certain headcount reductions that we implemented in March 2020 and will be reduced if our full-time headcount declines further, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%. We will be required to repay any portion of the outstanding principal that is not forgiven, along with accrued interest, in accordance with the amortization schedule described above, and we cannot provide any assurance that we will be eligible for loan forgiveness, that we will ultimately apply for forgiveness, or that any amount of the PPP Loan will ultimately be forgiven by the SBA. Furthermore, on April 28, 2020, the Secretary of the U.S. Department of the Treasury stated that the SBA will perform a full review of any PPP loan over $2.0 million before forgiving the loan.
In order to apply for the PPP Loan, we were required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support our ongoing operations. We made this certification in good faith after analyzing, among other things, our financial situation and access to alternative forms of capital, and believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan is consistent with the broad objectives of the Paycheck Protection Program of the CARES Act. The certification described above does not contain any objective criteria and is subject to interpretation. On April 23, 2020, the SBA issued guidance stating that it is unlikely that a public company with substantial market value and access to capital markets will be able to make the required certification in good faith. The lack of clarity regarding loan eligibility under the Paycheck Protection Program has resulted in significant media coverage and controversy with respect to public companies applying for and receiving loans. If, despite our good-faith belief that given our Company's circumstances we satisfied all eligible requirements for the PPP Loan, we are later determined to have violated any of the laws or governmental regulations that apply to us in connection with the PPP Loan, such as the False Claims Act, or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to penalties, including significant civil, criminal and administrative penalties and could be required to repay the PPP Loan in its entirety. In addition, receipt of a PPP Loan may result in adverse publicity and damage to reputation, and a review or audit by the SBA or other government entity or claims under the False Claims Act could consume significant financial and management resources. Any of these events could have a material adverse effect on our business, results of operations and financial condition.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4. MINE SAFETY DISCLOSURES
Not applicable.
Item 5. OTHER INFORMATION
None.
36

Table of Contents
Item 6. EXHIBITS
a) Index to Exhibits

Item No. |  | Exhibit
31.1(1) |  | Certification of Chief ExecutCertification of Chief Executive Officer under SEC Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934ve Officer under SEC Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934
31.2(1) |  | Certificate of Chief Financial Officer under SEC Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934
32.1(1) |  | Certification Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 Chief Executive Officer pursuant to 18 U.S.C. Section 1350
32.2(1) |  | Certification of Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 Financial Officer pursuant to 18 U.S.C. Section 1350
101.INS |  | XBRL Instance Document
101.SCH |  | XBRL Taxonomy Extension Schema Document
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document

_________________________________________
(1) Filed currently herewith.
37

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Nature’s Sunshine Products, Inc. |  |
Date: | August 6, 2020 | /s/ Terrence O. Moorehead
|  | Terrence O. Moorehead,
|  | President and Chief Executive Officer
Date: | August 6, 2020 | /s/ Joseph W. Baty
|  | Joseph W. Baty,
|  | Executive Vice President, Chief Financial Officer and Treasurer

38